Amicus Therapeutics Stock In The News

FOLD Stock  USD 11.86  0.43  3.76%   
The overall news coverage of Amicus Therapeutics from major news outlets shows solid bullish sentiment on 18 news articles, blog posts, and TV commentaries analyzed in the last few months. Our overall analysis of Amicus Therapeutics' news coverage and content from conventional and social sources shows investors' bearish mood towards Amicus Therapeutics. The specific impact of Amicus Therapeutics news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Amicus Therapeutics' overall financial health and prospects. It also depends on the type and quality of a news publisher.
  
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Amicus Therapeutics headlines in addition to utilizing other, more conventional financial analysis modules. Check out Amicus Therapeutics Backtesting and Amicus Therapeutics Hype Analysis.
For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.

Amicus Therapeutics Today Top News and Investor Outlook

Yahoo News
WuXi Biologics Reports Solid 2023 Annual Results
https://finance.yahoo.com/news/wuxi-biologics-reports-solid-2023-135300602.html
 Bullish
Yahoo News
Director Margaret Mcglynn Sells 15,000 Shares of Amicus Therapeutics Inc (FOLD)
https://finance.yahoo.com/news/director-margaret-mcglynn-sells-15-045608872.html
 Bullish
Yahoo News
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
https://finance.yahoo.com/news/amicus-therapeutics-inc-nasdaq-fold-141303147.html
 Bullish
Yahoo News
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2024
https://finance.yahoo.com/news/amicus-therapeutics-present-upcoming-investor-120000661.html
 Bullish
Yahoo News
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q4 2023 Earnings Call Transcript
https://finance.yahoo.com/news/amicus-therapeutics-inc-nasdaq-fold-162532961.html
 Bullish
Yahoo News
20 Fastest Growing Biotech Companies in the US
https://finance.yahoo.com/news/20-fastest-growing-biotech-companies-104317671.html
 Bullish
Yahoo News
Amicus Therapeutics to Announce Full Year 2023 Financial Results on February 28, 2024
https://finance.yahoo.com/news/amicus-therapeutics-announce-full-2023-120000380.html
 Bullish
Yahoo News
Amicus Therapeutics Stock Sees Improved Relative Strength Rating
https://finance.yahoo.com/m/05078f2a-d309-3d5e-8171-0ba0d7485e88/amicus-therapeutics-stock.html
 Bullish
Yahoo News
Amicus Therapeutics Receives the 2024 Ne...
https://finance.yahoo.com/news/amicus-therapeutics-receives-2024-treatment-120000803.html
 Neutral
Yahoo News
Amicus Therapeutics Announces Presentations and Posters at the 20th Annual WORLDSymposiumâ„¢ 2024
https://finance.yahoo.com/news/amicus-therapeutics-announces-presentations-posters-120000270.html
 Bullish

Amicus Therapeutics Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Amicus and other traded companies coverage. We help investors stay connected with Amicus headlines for the 28th of March to make an informed investment decision based on correlating the impacts of news items on Amicus Stock performance. Please note that trading solely based on the Amicus Therapeutics hype is not for everyone as timely availability and quick action are needed to avoid losses.
Amicus Therapeutics' linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Amicus Therapeutics investors visualize upcoming and past events in order to time the market based on Amicus Therapeutics noise-free hype analysis.
Amicus Therapeutics stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Amicus earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Amicus Therapeutics that are available to investors today. That information is available publicly through Amicus media outlets and privately through word of mouth or via Amicus internal channels. However, regardless of the origin, that massive amount of Amicus data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Amicus Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Amicus Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Amicus Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Amicus Therapeutics alpha.

Amicus Largest EPS Surprises

Earnings surprises can significantly impact Amicus Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2023-11-08
2023-09-30-0.08-0.070.0112 
2021-11-09
2021-09-30-0.17-0.19-0.0211 
2023-08-08
2023-06-30-0.12-0.15-0.0325 
2023-05-10
2023-03-31-0.15-0.18-0.0320 
2018-11-05
2018-09-30-0.28-0.31-0.0310 
2012-08-07
2012-06-30-0.23-0.20.0313 
View All Earnings Estimates

Amicus Therapeutics Stock Latest Headlines

Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Amicus Therapeutics Stock. Current markets are strongly bullish. About 72% of major world exchanges and indexes are currently up. See today's market update for more information.
Simply Wall St News at Macroaxis
27th of March 2024
Amicus Therapeutics, Inc. Looks Inexpensive But Perhaps Not Attractive Enough
at simplywall.st 
Yahoo News
20th of March 2024
Amicus Therapeutics Issues 2024 Environmental, Social, and Governance Report
at finance.yahoo.com 
news
11th of March 2024
Manifold Finance Price Hits 23.13 on Exchanges
at thelincolnianonline.com 
news
7th of March 2024
Manifold Finance 24 Hour Volume Hits 271,582.11
at thelincolnianonline.com 
news
5th of March 2024
Manifold Finance Hits Self Reported Market Capitalization of 133.07 Million
at thelincolnianonline.com 
Yahoo News
1st of March 2024
Amicus Therapeutics Full Year 2023 Earnings EPS Misses Expectations
at finance.yahoo.com 
news
23rd of February 2024
Amicus Therapeutics, Inc. Chairman John F. Crowley Sells 31,614 Shares
at thelincolnianonline.com 

Amicus Therapeutics Investors Sentiment

The influence of Amicus Therapeutics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Amicus. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Amicus Therapeutics' public news can be used to forecast risks associated with an investment in Amicus. The trend in average sentiment can be used to explain how an investor holding Amicus can time the market purely based on public headlines and social activities around Amicus Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Amicus Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Amicus Therapeutics' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Amicus Therapeutics' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Amicus Therapeutics.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Amicus Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Amicus Therapeutics' short interest history, or implied volatility extrapolated from Amicus Therapeutics options trading.
When determining whether Amicus Therapeutics is a strong investment it is important to analyze Amicus Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Amicus Therapeutics' future performance. For an informed investment choice regarding Amicus Stock, refer to the following important reports:
Check out Amicus Therapeutics Backtesting and Amicus Therapeutics Hype Analysis.
For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.
You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.

Complementary Tools for Amicus Stock analysis

When running Amicus Therapeutics' price analysis, check to measure Amicus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amicus Therapeutics is operating at the current time. Most of Amicus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Amicus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amicus Therapeutics' price. Additionally, you may evaluate how the addition of Amicus Therapeutics to your portfolios can decrease your overall portfolio volatility.
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
AI Investment Finder
Use AI to screen and filter profitable investment opportunities
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Is Amicus Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amicus Therapeutics. If investors know Amicus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amicus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.51)
Revenue Per Share
1.353
Quarterly Revenue Growth
0.306
Return On Assets
(0.06)
Return On Equity
(1.07)
The market value of Amicus Therapeutics is measured differently than its book value, which is the value of Amicus that is recorded on the company's balance sheet. Investors also form their own opinion of Amicus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Amicus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amicus Therapeutics' market value can be influenced by many factors that don't directly affect Amicus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amicus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amicus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amicus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.